When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Prevention of migraine attacks - Wikipedia

   en.wikipedia.org/wiki/Prevention_of_migraines

   Feverfew has traditionally been used as a treatment for fever, headache and migraine, women's conditions such as difficulties in labour and regulation of menstruation, relief of stomach ache, toothache and insect bites. During the last decades, it has mainly been used for headache and as a preventive treatment for migraine. [63]

3. How to Find the Best Treatment for Your Migraines - AOL

   www.aol.com/lifestyle/best-treatment-migraines...

   Experts explain proven and new rescue therapies and migraine prevention protocols as well as which patients should and shouldn't try them. How to Find the Best Treatment for Your Migraines Skip to ...

4. Excedrin (brand) - Wikipedia

   en.wikipedia.org/wiki/Excedrin_(brand)

   Excedrin is an over-the-counter headache pain reliever, typically in the form of tablets or caplets. It contains paracetamol, aspirin and caffeine . It was manufactured by Bristol-Myers Squibb until it was purchased by Novartis in July 2005 along with other products from BMS's over-the-counter business.

5. Tanacetum parthenium - Wikipedia

   en.wikipedia.org/wiki/Tanacetum_parthenium

   In traditional medicine, feverfew has been used to treat headache, but there is no confirmed scientific evidence that it has any effect. [2] [10] [8] Feverfew is registered as a traditional herbal medicine in the Nordic countries under the brand name Glitinum. Only powdered feverfew is approved in the European Union herbal monograph. [11]

6. How Heat Can Be Both A Culprit And A Cure For Migraines - AOL

   www.aol.com/news/heat-both-culprit-cure...

   Heat can act as both a notorious trigger or a soothing remedy for migraines. We dug into the intricate balance pain sufferers must navigate. How Heat Can Be Both A Culprit And A Cure For Migraines

7. FDA approves first drug to prevent migraines - AOL

   www.aol.com/news/2018-05-18-fda-approves-first...

   Novartis reported that in a Phase 3b study, patients with episodic migraines who have failed two to four prior treatments had almost three-fold higher odds of having their migraine days cut in ...